Skip to main content
Erschienen in:

22.08.2016

Stage-Specific Embryonic Antigen-1 (SSEA-1) Expression in Thyroid Tissues

verfasst von: Jin Xu, Heather Hardin, Ranran Zhang, Kaitlin Sundling, Darya Buehler, Ricardo V. Lloyd

Erschienen in: Endocrine Pathology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Stage-specific embryonic antigen-1 (SSEA-1), also known as CD15, is a member of a cluster of differentiation antigens that have been identified in various normal tissues and in different types of cancers including papillary and medullary thyroid carcinoma. SSEA-1 may be expressed in normal stem cells and cancer stem-like cells. To evaluate the potential diagnostic and prognostic utility of SSEA-1 in thyroid tumors, we analyzed the expression of SSEA-1 in normal and neoplastic thyroid tissues by immunohistochemistry (IHC) using a tissue microarray with 158 different tissue cores. To evaluate the potential utility of SSEA-1 as a surface marker, we also assessed the expression of SSEA-1 in thyroid cell lines by flow cytometric analysis. SSEA-1 immunoreactivity was identified in malignant thyroid follicular epithelial cancers but not in the benign thyroid tissues. Anaplastic thyroid (ATC) (80 %) and conventional papillary thyroid carcinoma (PTC) (60.7 %) showed significantly higher percentage of cases that were SSEA-1 immunoreactive than follicular variant of papillary thyroid carcinoma (FVPTC) (20.6 %) and follicular carcinoma (FCA) (32.1 %). Flow cytometric analysis of cultured thyroid cell lines showed that a small subpopulation of ATC and PTC thyroid tumor cells had SSEA-1 immunoreactivity which may represent thyroid cancer stem-like cells. The ATC cells expressed more SSEA-1 immunoreactive cells than the PTC cell lines. Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas. SSEA-1 is a marker that detects malignant thyroid neoplasms in formalin-fixed paraffin-embedded thyroid tissue sections and may be a useful marker for thyroid cancer stem-like cells.
Literatur
1.
Zurück zum Zitat Hanjan SNS, Kearney JF, Cooper MD. A monoclonal antibody (MMA) that identifies a differentiation antigen on human myelomonocytic cells. Clin Immunol Immunopathol. 23:172–188, 1982.CrossRefPubMed Hanjan SNS, Kearney JF, Cooper MD. A monoclonal antibody (MMA) that identifies a differentiation antigen on human myelomonocytic cells. Clin Immunol Immunopathol. 23:172–188, 1982.CrossRefPubMed
2.
Zurück zum Zitat Hsu SM, Jaffe ES. Leu-M1 and peanut agglutinin stain the neoplastic cells of Hodgkin’s disease. Am J Clin Pathol. 82:29–32, 1984.CrossRefPubMed Hsu SM, Jaffe ES. Leu-M1 and peanut agglutinin stain the neoplastic cells of Hodgkin’s disease. Am J Clin Pathol. 82:29–32, 1984.CrossRefPubMed
3.
Zurück zum Zitat Jang TJ, Park JB, Lee JI. The Expression of CD10 and CD15 Is Progressively Increased during Colorectal Cancer Development. Korean J Pathol, 47:340–347, 2003.CrossRef Jang TJ, Park JB, Lee JI. The Expression of CD10 and CD15 Is Progressively Increased during Colorectal Cancer Development. Korean J Pathol, 47:340–347, 2003.CrossRef
4.
Zurück zum Zitat Kadota A, Masutani M, Takei M, Horie T. Evaluation of expression of CD15 and sCD15 in non-small cell lung cancer. Int J Oncol. 15:1081–1089, 1999.PubMed Kadota A, Masutani M, Takei M, Horie T. Evaluation of expression of CD15 and sCD15 in non-small cell lung cancer. Int J Oncol. 15:1081–1089, 1999.PubMed
5.
Zurück zum Zitat Brooks SA, Leathem AJ. Expression of the CD15 antigen (Lewis x) in breast cancer. Histochem J. 27:689–693, 1995.CrossRefPubMed Brooks SA, Leathem AJ. Expression of the CD15 antigen (Lewis x) in breast cancer. Histochem J. 27:689–693, 1995.CrossRefPubMed
6.
Zurück zum Zitat Shirahama T, Ikoma M, Muramatsu T, Ohi Y. Expression of SSEA-1 carbohydrate antigen correlates with stage, grade and metastatic potential of transitional cell carcinoma of the bladder. J Urol. 148:1319–1322, 1992.PubMed Shirahama T, Ikoma M, Muramatsu T, Ohi Y. Expression of SSEA-1 carbohydrate antigen correlates with stage, grade and metastatic potential of transitional cell carcinoma of the bladder. J Urol. 148:1319–1322, 1992.PubMed
7.
Zurück zum Zitat Miettinen M, Kärkkäinen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch. 429:213–219, 1996.PubMed Miettinen M, Kärkkäinen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch. 429:213–219, 1996.PubMed
8.
Zurück zum Zitat Fonseca E, Castanhas S, Sobrinho-Simões M. Carbohydrate antigens as oncofetal antigens in papillary carcinoma of the thyroid gland. Endocr Pathol. 8:301–303, 1997.CrossRefPubMed Fonseca E, Castanhas S, Sobrinho-Simões M. Carbohydrate antigens as oncofetal antigens in papillary carcinoma of the thyroid gland. Endocr Pathol. 8:301–303, 1997.CrossRefPubMed
9.
Zurück zum Zitat Fonseca E, Castanhas S, Sobrinho-Simões M. Expression of simple mucin type antigens and Lewis type 1 and type 2 chain antigens in the thyroid gland. An immunohistochemical study of normal thyroid tissues, benign lesions and malignant tumors. Endocr Pathol. 7:291–301, 1996.CrossRefPubMed Fonseca E, Castanhas S, Sobrinho-Simões M. Expression of simple mucin type antigens and Lewis type 1 and type 2 chain antigens in the thyroid gland. An immunohistochemical study of normal thyroid tissues, benign lesions and malignant tumors. Endocr Pathol. 7:291–301, 1996.CrossRefPubMed
10.
Zurück zum Zitat Van Hoeven KH, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol. 18:93–97, 1998.CrossRefPubMed Van Hoeven KH, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol. 18:93–97, 1998.CrossRefPubMed
11.
Zurück zum Zitat Koo JS, Shin E, Hong SW. Immunohistochemical characteristics of diffuse sclerosing variant of papillary carcinoma: comparison with conventional papillary carcinoma. APMIS. 118:744–752, 2010.CrossRefPubMed Koo JS, Shin E, Hong SW. Immunohistochemical characteristics of diffuse sclerosing variant of papillary carcinoma: comparison with conventional papillary carcinoma. APMIS. 118:744–752, 2010.CrossRefPubMed
12.
Zurück zum Zitat Ohta M, Ookoshi T, Naiki H, Imamura Y. HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma. Pathol Int. 65:119–125, 2015.CrossRefPubMed Ohta M, Ookoshi T, Naiki H, Imamura Y. HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma. Pathol Int. 65:119–125, 2015.CrossRefPubMed
13.
Zurück zum Zitat Schr/Sder S, Schwarz W, Rehpenning W, Loning T, Becker W. Prognostic significance of Leu-M1 immunostaining in papillary carcinomas of the thyroid gland. Virchows Arch. 411:435–439, 1998.CrossRef Schr/Sder S, Schwarz W, Rehpenning W, Loning T, Becker W. Prognostic significance of Leu-M1 immunostaining in papillary carcinomas of the thyroid gland. Virchows Arch. 411:435–439, 1998.CrossRef
14.
Zurück zum Zitat Willgeroth C, Floegel R, Rosler B. The importance of S-100 protein positive Langerhans cells and Leu-M1 positive tumor cells for prognosis of papillary thyroid cancer. Zentralbl Chir. 117:603–606, 1992.PubMed Willgeroth C, Floegel R, Rosler B. The importance of S-100 protein positive Langerhans cells and Leu-M1 positive tumor cells for prognosis of papillary thyroid cancer. Zentralbl Chir. 117:603–606, 1992.PubMed
15.
Zurück zum Zitat Neuhold N, Langle F, Gnant M, Hollenstein U, Niederie B. Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma. J Cancer Res Clin Oncol. 118:629–634, 1992.CrossRefPubMed Neuhold N, Langle F, Gnant M, Hollenstein U, Niederie B. Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma. J Cancer Res Clin Oncol. 118:629–634, 1992.CrossRefPubMed
16.
Zurück zum Zitat Langel F, Soliman T, Neuhold N, Widhalm G, Niederie B, Roka S, Kaserer K, Blauensteiner W, Dam K, Clodi M, et al. CD15 (LeuM1) immunoreactivity: prognostic factor for sporadic and hereditary medullary thyroid cancer? Study Group on Multiple Endocrine Neoplasia of Austria. World J Surg. 18:583–587, 1994. Langel F, Soliman T, Neuhold N, Widhalm G, Niederie B, Roka S, Kaserer K, Blauensteiner W, Dam K, Clodi M, et al. CD15 (LeuM1) immunoreactivity: prognostic factor for sporadic and hereditary medullary thyroid cancer? Study Group on Multiple Endocrine Neoplasia of Austria. World J Surg. 18:583–587, 1994.
17.
Zurück zum Zitat Ma R, Bonnefond S, Morshed SA, Latif R, Davies TF. Stemness is derived from thyroid cancer cells. Front Endocrinol (Lausanne). 5:114, 2014. Ma R, Bonnefond S, Morshed SA, Latif R, Davies TF. Stemness is derived from thyroid cancer cells. Front Endocrinol (Lausanne). 5:114, 2014.
18.
Zurück zum Zitat Ma R, Minsky N, Morshed SA, Davies TF. Stemness in human thyroid cancers and derived cell lines: the role of asymmetrically dividing cancer stem cells resistant to chemotherapy. J Clin Endocrinol Metab. 99:E400–E409, 2014.CrossRefPubMedPubMedCentral Ma R, Minsky N, Morshed SA, Davies TF. Stemness in human thyroid cancers and derived cell lines: the role of asymmetrically dividing cancer stem cells resistant to chemotherapy. J Clin Endocrinol Metab. 99:E400–E409, 2014.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Hardin H Guo Z, Shan W, Montemayor-Garcia C, Asioli S, Yu X-M, Harrison AD, Chen H, Lloyd RV. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol 184:2342–2354, 2014.CrossRefPubMedPubMedCentral Hardin H Guo Z, Shan W, Montemayor-Garcia C, Asioli S, Yu X-M, Harrison AD, Chen H, Lloyd RV. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol 184:2342–2354, 2014.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Hardin H, Yu X-M, Harrison AD et al. Generation of Novel thyroid cancer stem-like cell clones: Effects of resveratrol and valproic acid. Am J Pathol. 186:1662–1673, 2016..CrossRefPubMed Hardin H, Yu X-M, Harrison AD et al. Generation of Novel thyroid cancer stem-like cell clones: Effects of resveratrol and valproic acid. Am J Pathol. 186:1662–1673, 2016..CrossRefPubMed
22.
Zurück zum Zitat Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, Chen H, Lloyd RV. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol 26:54–61, 2013.CrossRefPubMed Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, Chen H, Lloyd RV. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol 26:54–61, 2013.CrossRefPubMed
23.
Zurück zum Zitat Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor initiating cells in human glioblastoma. Cell Stem Cell 4:440–442, 2009.CrossRefPubMed Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor initiating cells in human glioblastoma. Cell Stem Cell 4:440–442, 2009.CrossRefPubMed
24.
Zurück zum Zitat Kim Y, Jeong J, Kang H, Lim J, Heo J, Ratajczak J, Ratajczak MZ, Shin DM, The molecular nature of very small embryonic-like stem cells in adult tissues. J Stem Cells 7: 55–62, 2014.CrossRef Kim Y, Jeong J, Kang H, Lim J, Heo J, Ratajczak J, Ratajczak MZ, Shin DM, The molecular nature of very small embryonic-like stem cells in adult tissues. J Stem Cells 7: 55–62, 2014.CrossRef
25.
Zurück zum Zitat Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol doi:10.1001/jamaoncol.2016.0386, 2016. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol doi:10.​1001/​jamaoncol.​2016.​0386, 2016.
27.
Zurück zum Zitat Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66: 9339–9344, 2006.CrossRefPubMed Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66: 9339–9344, 2006.CrossRefPubMed
28.
Zurück zum Zitat Son MJ, Woolard K, Nam DH, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 4:440–452, 2009.CrossRefPubMed Son MJ, Woolard K, Nam DH, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 4:440–452, 2009.CrossRefPubMed
29.
Zurück zum Zitat Read TA, Fogarty MP, Markant SL, et al. Identification of CD15 as a marker for tumor- propagating cells cells in a mouse model of medulloblastoma. Cancer Cell. 15:135–147, 2009.CrossRefPubMedPubMedCentral Read TA, Fogarty MP, Markant SL, et al. Identification of CD15 as a marker for tumor- propagating cells cells in a mouse model of medulloblastoma. Cancer Cell. 15:135–147, 2009.CrossRefPubMedPubMedCentral
Metadaten
Titel
Stage-Specific Embryonic Antigen-1 (SSEA-1) Expression in Thyroid Tissues
verfasst von
Jin Xu
Heather Hardin
Ranran Zhang
Kaitlin Sundling
Darya Buehler
Ricardo V. Lloyd
Publikationsdatum
22.08.2016
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 4/2016
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-016-9448-1

Neu im Fachgebiet Pathologie

DNA mixture deconvolution using fully continuous models EuroForMix and EFMrep

  • Open Access
  • Originalien

Mixture deconvolution is a powerful tool for inferring individual DNA profiles from DNA mixtures for subsequent transmission to a database or database queries. To carry out deconvolution, a mixed trace can be interpreted either manually by an …

Energie und Verletzungspotenzial von gezielt aus einem Fahrzeug abgeworfenen Steinen nach Durchschlag durch eine Pkw-Windschutzscheibe

Wir berichten aus Anlass eines Strafverfahrens über Versuche und deren biomechanische Bewertung hinsichtlich des möglichen Verletzungspotenzials von Steinen, welche vorsätzlich im Begegnungsverkehr auf entgegenkommende Fahrzeuge geworfen werden …

Durchführungsrealität der Komplexmethode zur Todeszeiteingrenzung an deutschen rechtsmedizinischen Instituten

Die Komplexmethode nach Henssge und Madea gilt als der Goldstandard für die Eingrenzung des Todeszeitintervalls im frühen postmortalen Intervall [ 1 , 2 ]. Der temperaturbasierte Methodenanteil gilt als gut etabliert [ 1 ]. Dies gilt nur mit …

Stellungnahme der Spurenkommission zu Ringversuchen zum Zweck der Qualitätssicherung in forensisch-molekulargenetischen Laboratorien

Die Spurenkommission wurde in den 1980er-Jahren gegründet und bildet eine Arbeitsgruppe innerhalb der Deutschen Gesellschaft für Rechtsmedizin (DGRM). Zu den Kernaufgaben der Spurenkommission gehören das Verfassen von Empfehlungen für die …